Trinity Biotech (TRIB) Stock Statistics & Valuation Metrics

Trinity Biotech has a market cap or net worth of $7.28M. The enterprise value is $102.30M.

Trinity Biotech has 19,194,080 shares outstanding. The number of shares has decreased by -2.65% in one year.

Trinity Biotech’s return on equity (ROE) is 1.00 and return on invested capital (ROIC) is -58.31%.

The current PE Ratio of Trinity Biotech is -0.69. Trinity Biotech’s PEG ratio is 0.01.

In the last 12 months, Trinity Biotech had revenue of 56.83M and earned -24.02M in profits. Earnings per share was -0.16.

In the last 12 months, operating cash flow was -12.49M and capital expenditures -8.22M, giving a free cash flow of -18.73M billion.

Trinity Biotech pays an annual dividend of $1.095, resulting in a dividend yield of ―

Trinity Biotech upcoming earnings date is May 21, 2025, TBA Not Confirmed.

Trinity Biotech as a current ratio of 2.60, with Debt / Equity ratio of -355.76%

In the past 12 months, Trinity Biotech has paid -59.00K in taxes.

Trinity Biotech EV to EBITDA ratio is -16.30, with an EV/FCF ratio of -27.55.

Trinity Biotech has $2.84M in cash and marketable securities with $29.88M in debt, giving a net cash position of $90.88M billion.

Gross margin is 34.07%, with operating margin of -47.59%, and net profit margin of -42.26%.

The average price target for Trinity Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―